{"id":"zilbrix","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Dehydration"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting this enzyme, Zilbrix helps to reduce the levels of a certain substance in the body, which in turn helps to manage the symptoms of a specific condition.","oneSentence":"Zilbrix inhibits the activity of a specific enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:19.438Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT00678301","phase":"PHASE3","title":"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-18","conditions":"Infections, Streptococcal","enrollment":365},{"nctId":"NCT01106092","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-13","conditions":"Haemophilus Influenzae Type b, Tetanus, Hepatitis B","enrollment":312},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT00473668","phase":"PHASE3","title":"Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-01","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Tetanus","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DTPw-HBV Kft"],"phase":"phase_3","status":"active","brandName":"Zilbrix™","genericName":"Zilbrix™","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Zilbrix inhibits the activity of a specific enzyme. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}